M
Michael Brown
Researcher at St. Jude Children's Research Hospital
Publications - 22
Citations - 2286
Michael Brown is an academic researcher from St. Jude Children's Research Hospital. The author has contributed to research in topics: Immune system & Cytotoxic T cell. The author has an hindex of 15, co-authored 21 publications receiving 2245 citations. Previous affiliations of Michael Brown include Royal Adelaide Hospital & Center for Cell and Gene Therapy.
Papers
More filters
Journal ArticleDOI
Stat5a and Stat5b Proteins Have Essential and Nonessential, or Redundant, Roles in Cytokine Responses
Stephan Teglund,Catriona McKay,Erin G. Schuetz,Jan M. van Deursen,Dimitrios J. Stravopodis,Demin Wang,Michael Brown,Sara Bodner,Gerard Grosveld,James N. Ihle,James N. Ihle +10 more
TL;DR: The phenotypes of the mice demonstrate an essential, and often redundant, role for the two Stat5 proteins in a spectrum of physiological responses associated with growth hormone and prolactin.
Journal ArticleDOI
Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice
Michael Brown,David J. Topham,Mark Y. Sangster,Jingfeng Zhao,Kirsten J. Flynn,Sherri L. Surman,David L. Woodland,Peter C. Doherty,Andrew G. Farr,Paul K. Pattengale,Malcolm K. Brenner +10 more
TL;DR: It is shown that constitutive (rather than tightly regulated), low-level expression of CD40L can produce abnormal proliferative responses in developing T lymphocytes, apparently through aberrant interaction betweenCD40L+ and TCRαβ+CD40+ thymocytes.
Journal ArticleDOI
CD40 ligand induces an antileukemia immune response in vivo.
Dagmar Dilloo,Michael Brown,Marie Roskrow,Wanyung Zhong,Martha Holladay,William Holden,Malcolm K. Brenner +6 more
TL;DR: The results suggest a means by which CD40+ leukemia cells may be rendered immunogenic in vivo and show the protective effects against A20 cells to be mediated by a combination of CD4+ and CD8+ T lymphocytes and by natural killer cells.
Journal ArticleDOI
IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma
Laura C. Bowman,Michael Grossmann,Michael Grossmann,Donna Rill,Donna Rill,Michael Brown,Michael Brown,Wan Yun Zhong,Wan Yun Zhong,Barbara Alexander,Barbara Alexander,Thasia Leimig,Thasia Leimig,Elaine Coustan-Smith,Elaine Coustan-Smith,Dario Campana,Dario Campana,Jesse J. Jenkins,Jesse J. Jenkins,Diane Woods,Diane Woods,Geoffrey R. Kitchingman,Geoffrey R. Kitchingman,Elio F. Vanin,Elio F. Vanin,Malcolm K. Brenner +25 more
TL;DR: A promising correlation between preclinical observations and clinical outcome in neuroblastoma is shown, and further exploration of the approach for malignant diseases of children is supported.
Journal ArticleDOI
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
Raphael Rousseau,Ettore Biagi,Ettore Biagi,Ettore Biagi,Aurelie Dutour,Aurelie Dutour,Aurelie Dutour,Eric Yvon,Michael Brown,Michael Brown,Michael Brown,Tiffany F. Lin,Tiffany F. Lin,Tiffany F. Lin,Zhuyong Mei,Zhuyong Mei,Zhuyong Mei,Bambi Grilley,Bambi Grilley,Bambi Grilley,Edwina J. Popek,Edwina J. Popek,Edwina J. Popek,Helen E. Heslop,Helen E. Heslop,Helen E. Heslop,Adrian P. Gee,Adrian P. Gee,Adrian P. Gee,Robert A. Krance,Robert A. Krance,Robert A. Krance,Uday R. Popat,George Carrum,George Carrum,George Carrum,Judith F. Margolin,Judith F. Margolin,Judith F. Margolin,Malcolm K. Brenner +39 more
TL;DR: Even in heavily treated patients, including recipients of allogeneic stem cell transplants, recipient-derived antileukemia vaccines can induce immune responses reactive against leukemic blasts, and this approach may be worthy of further study, particularly in patients with a high risk of relapse.